Objective: Extensive exposure to prescription-type opioids has resulted in major harm worldwide, calling for better-adapted approaches to opioid agonist therapy. The authors aimed to determine whether flexible take-home buprenorphine/naloxone is as effective as supervised methadone in reducing opioid use in prescription-type opioid consumers with opioid use disorder.
Methods: This seven-site, pan-Canadian, 24-week, pragmatic, open-label, noninferiority, two-arm parallel randomized controlled trial involved treatment-seeking adults with prescription-type opioid use disorder. Participants were randomized in a 1:1 ratio to treatment with sublingual buprenorphine/naloxone (target dosage, 8 mg/2 mg to 24 mg/6 mg per day; flexible take-home dosing) or oral methadone (≈60-120 mg/day; closely supervised). The primary outcome was the proportion of opioid-free urine drug screens over 24 weeks (noninferiority margin, 15%). All randomized participants were analyzed, excluding one who died shortly after randomization, for the primary analysis (modified intention-to-treat analysis).
Results: Of 272 participants recruited (mean age, 39 years [SD=11]; 34.2% female), 138 were randomized to buprenorphine/naloxone and 134 to methadone. The mean proportion of opioid-free urine drug screens was 24.0% (SD=34.4) in the buprenorphine/naloxone group and 18.5% (SD=30.5) in the methadone group, with a 5.6% adjusted mean difference (95% CI=-0.3, +∞). Participants in the buprenorphine/naloxone group had 0.47 times the odds (95% CI=0.24, 0.90) of being retained in the assigned treatment compared with those in the methadone group. Overall, 24 drug-related adverse events were reported (12 in the buprenorphine/naloxone group [N=8/138; 5.7%] and 12 in the methadone group [N=12/134; 9.0%]) and mostly included withdrawal, hypogonadism, and overdose.
Conclusions: The buprenorphine/naloxone flexible model of care was safe and noninferior to methadone in reducing opioid use among people with prescription-type opioid use disorder. This flexibility could help expand access to opioid agonist therapy and reduce harms in the context of the opioid overdose crisis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.ajp.21090964 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Opioid prescribing in the Netherlands during the COVID-19 pandemic: a national register-based study.
BMJ Open
August 2024
Department of Anesthesiology, Leiden University Medical Center, Leiden, Netherlands.
Objectives: The COVID-19 pandemic and related lockdown measures disrupted global healthcare provision, including opioid prescribing. In North America, opioid sales declined while opioid-related deaths increased. In Europe, the effect of the pandemic on prescribing is not yet known.
View Article and Find Full Text PDFImpact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder in Canada.
Am J Addict
November 2024
British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
Article Synopsis
- The study investigates the effects of methamphetamine and amphetamine use on the retention of opioid agonist therapy (OAT) among individuals with prescription opioid use disorder (POUD) in Canada.
- About 45.9% of the 209 participants had positive urine tests for methamphetamine/amphetamine, which was linked to significantly shorter times in OAT—21 days compared to 168 days for those without stimulant use.
- Findings suggest that addressing stimulant use in individuals undergoing OAT could enhance treatment retention and overall outcomes.
Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada.
Drug Alcohol Rev
November 2024
British Columbia Centre on Substance Use, Vancouver, Canada.
Article Synopsis
- The study focuses on rising methamphetamine/amphetamine use among individuals with prescription-type opioid use disorder (POUD) in North America, particularly those starting treatments like methadone or buprenorphine/naloxone.
- Using logistic regression, the research examined factors linked to methamphetamine use in a sample of 269 participants, finding significant correlations with positive fentanyl tests, recent non-fatal overdoses, and previous opioid treatment exposure.
- The findings highlight the connection between methamphetamine use and severe opioid use disorder markers, indicating a need for targeted interventions to improve treatment and reduce overdose risks in this vulnerable population.
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial.
J Dual Diagn
June 2024
Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.
Objective: To evaluate the impact of depressive symptom severity on opioid use and treatment retention in individuals with prescription-type opioid use disorder (POUD).
Method: We analyzed data from a multi-centric, pragmatic, open-label, randomized controlled trial comparing buprenorphine/naloxone to methadone models of care in 272 individuals with POUD. Opioid use was self-reported every two weeks for 24 weeks using the Timeline Followback.
Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial.
Addict Behav
July 2024
Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, 2900 boul. Edouard-Montpetit, Montréal, Québec H3T 1J4, Canada; Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 Saint-Denis Street, Montréal, Québec H2X 0A9, Canada. Electronic address:
Background: The relationship between opioid craving and opioid use is unclear. We sought to determine to what extent craving mediated the relationship between opioid agonist therapy and changes in opioid use.
Methods: Data came from a pragmatic, 24-week, pan-Canadian, multi-centric, open-label, randomized controlled trial comparing flexible buprenorphine/naloxone take-home doses to standard supervised methadone models of care for the treatment of prescription-type opioid use disorder.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!